BDF Gestion Sells 5,337 Shares of Hologic, Inc. $HOLX

Key Points

• BDF Gestion decreased its stock position in Hologic, Inc. by 9.8%, holding 48,975 shares worth $3.19 million after selling 5,337 shares in the second quarter.
• Hologic's earnings per share for the last quarter was $1.08, beating analyst estimates, while the company has set its Q4 2025 guidance between 1.090-1.120 EPS.
• Approximately 94.73% of Hologic's stock is owned by institutional investors and hedge funds, indicating strong institutional confidence in the company.

BDF Gestion trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,975 shares of the medical equipment provider's stock after selling 5,337 shares during the period. BDF Gestion's holdings in Hologic were worth $3,191,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the company. IFM Investors Pty Ltd boosted its position in Hologic by 4.5% during the second quarter. IFM Investors Pty Ltd now owns 55,335 shares of the medical equipment provider's stock valued at $3,606,000 after buying an additional 2,366 shares during the period. Family Legacy Financial Solutions LLC bought a new position in Hologic in the second quarter worth about $211,000. Wealth Enhancement Advisory Services LLC increased its stake in shares of Hologic by 71.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 10,909 shares of the medical equipment provider's stock valued at $707,000 after purchasing an additional 4,548 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of Hologic by 2.4% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 89,060 shares of the medical equipment provider's stock valued at $5,803,000 after purchasing an additional 2,100 shares in the last quarter. Finally, Swedbank AB grew its holdings in shares of Hologic by 3.5% during the second quarter. Swedbank AB now owns 1,044,262 shares of the medical equipment provider's stock valued at $68,044,000 after buying an additional 35,469 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on HOLX shares. UBS Group lifted their price target on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, July 31st. Stephens restated an "overweight" rating and set a $78.00 price target on shares of Hologic in a research note on Thursday. Argus increased their price target on shares of Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a report on Friday. Evercore ISI increased their target price on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Finally, Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $79.38.

Hologic Trading Down 2.8%

Shares of Hologic stock traded down $1.94 during trading hours on Friday, hitting $66.33. The company's stock had a trading volume of 8,515,121 shares, compared to its average volume of 2,111,449. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The stock has a 50 day moving average of $66.47 and a 200 day moving average of $62.75. The company has a market capitalization of $14.75 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 2.40 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the firm posted $1.06 earnings per share. The business's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.